drugset / Trial / NCT03156231
Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease
Phase 4
Completed
185 enrolled
University of Zurich
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Randomized, placebo controlled trial evaluating efficacy of acetazolamide in preventing altitude related adverse health effects (ARAHE) in lowlanders with chronic obstructive lung disease travelling from 760 m to 3200 m.
Timeline
- Start
- 2017-05-24
- Primary completion
- 2018-08-02
- Completion
- 2018-08-02
Publications
- Schmuziger YA, Mademilov M, Buergin A, Scheiwiller PM, Mayer L, Schneider SR, Lichtblau M, Bitos K, Muralt L, Muller J, Akylbekov A, Mirzalieva G, Sooronbaev TM, Ulrich S, Bloch KE, Furian M. Nocturnal cerebral oxygenation in patients with COPD at altitude: data from a randomized clinical trial of acetazolamide. J Clin Sleep Med. 2025 Dec 1;21(12):2051-2061. doi: 10.5664/jcsm.11868.
- Christen M, Buergin A, Mademilov M, Mayer L, Schneider SR, Lichtblau M, Sooronbaev TM, Ulrich S, Bloch KE, Furian M. Electrocardiographic signs of cardiac ischemia at rest and during exercise in patients with COPD traveling to 3,100 m: data from a randomized trial of acetazolamide. Front Cardiovasc Med. 2025 Feb 6;12:1524201. doi: 10.3389/fcvm.2025.1524201. eCollection 2025.
- Furian M, Mademilov M, Buergin A, Scheiwiller PM, Mayer L, Schneider S, Emilov B, Lichtblau M, Bitos K, Muralt L, Groth A, Reiser AE, Sevik A, Sheraliev U, Marazhapov NH, Aydaralieva S, Muratbekova A, Tabyshova A, Abdraeva A, Buenzli S, Sooronbaev TM, Ulrich S, Bloch KE. Acetazolamide to Prevent Adverse Altitude Effects in COPD and Healthy Adults. NEJM Evid. 2022 Jan;1(1):EVIDoa2100006. doi: 10.1056/EVIDoa2100006. Epub 2021 Dec 22.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acetazolamide | Small molecule | 375 mg | Oral |